Find FDA Investigational New Drug (IND) Submissions for Hepatology (Liver, Pancreatic, Gall Bladder) in UNITED STATES

Lead Product(s): TLY012

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $5.9 million Upfront Cash: Undisclosed

Deal Type: Funding January 30, 2020

Details:

Theraly Fibrosis has been awarded a Small Business Innovation Research Phase II grant by the National Institutes of Health to support development of TLY012 for treatment of chronic pancreatitis.